News

The FDA has also approved BeOne’s application to participate in Project Orbis, an initiative that offers a framework for concurrent submission and oncology products review among collaborating health

ADCE-D01 is an antibody-drug conjugate (ADC) designed to target the urokinase plasminogen activator receptor-associated protein (uPARAP). Preclinical data indicate that ADCE-D01 exhibits anti-tumour activity in mesenchymal tumour models,

BAT2506 is a proposed biosimilar of golimumab, developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that specifically targets tumour necrosis factor alpha (TNF-α), a key pro-inflammatory

The funding will facilitate the establishment of Nilo’s laboratories in New York City, the growth of the team, and the advancement of preclinical programmes. Furthermore, the company has appointed

The funds will be used to advance the late-stage clinical development of the company’s leading candidate, inhaled AERO-007. This nebulised LABA/LAMA combination is being developed as a potential

Orca-T is being assessed to treat hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and acute lymphoblastic leukaemia (ALL). The FDA has granted priority review, with

Currently, there are no approved treatments for CIAS, a key feature of the condition that significantly affects daily functioning and the quality of life for individuals living with

The oral treatment was approved for use on those who continue to experience symptoms despite receiving H1 antihistamine therapy. Rhapsido is administered in pill form twice daily and

The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within